NuGEN enables next-generation
sequencing of DNA and RNA from FFPE samples
3 Nov 2010
NuGEN Technologies is making available the first commercial
products using next-generation sequencing (NGS) technologies to analyze
nucleic acids extracted from Formalin-Fixed Paraffin-Embedded (FFPE)
The new products, Ovation WGA FFPE and Ovation RNA-Seq FFPE,
complement NuGEN’s current FFPE products, which are widely used for
RNA analysis on microarrays.
Now, researchers can analyze either RNA or DNA from FFPE tissue
samples using expression microarrays, array-based comparative
genomic hybridization (aCGH) or NGS.
With reduced sample input requirements and high fidelity
sequencing results sufficient to detect single nucleotide
variations, NuGEN’s linear amplification enables preservation of
copy number changes with small amounts of starting DNA without risk
of forming chimeras or polymerase error propagation. The Ovation WGA
FFPE System is the only whole genome amplification solution to
provide sufficient yields to enable analysis by both aCGH and NGS
from a single reaction.
The Ovation RNA-Seq FFPE System is the first sample preparation
solution for transcriptome profiling with FFPE tissue. In just six
hours, it produces double-stranded cDNA ready for library
construction on all leading NGS platforms.
“While ideal for retrospective studies, scientists have been
hesitant to consume FFPE tissue blocks since they are a finite
resource and there was a trade-off between amounts used and data
quality,” said Dr. Doug Amorese, vice president of research and
development at NuGEN.
“With our full suite of Ovation products for FFPE,
researchers can work with the smallest, most difficult RNA and DNA
samples and unlock a repository of indispensable genomic data.”
Currently, there are at least 400 million archived FFPE samples
in North America alone, containing vital information for clinical
research in areas ranging from cancer to infectious disease.
With both the Ovation WGA FFPE System and the Ovation RNA-Seq
FFPE System, customers can leverage the power of NuGEN’s proven SPIA
technology to explore the genomic state of these tissues with either
arrays or NGS technologies.
“With our newest Ovation offerings, we’re once again expanding
the limits of what is possible in genomics, bringing the assay
development expertise we’re known for to broader sample
applications,” said Elizabeth Hutt, chief executive officer of NuGEN.
“We’re committed to enabling researchers with solutions that provide
the highest quality data from any sample — no matter how small,
degraded or difficult — to help scientists on their quest to improve
the overall quality of human health.”